Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from HCW Biologics ( (HCWB) ).
HCW Biologics Inc., a clinical-stage biopharmaceutical developer of novel immunotherapies targeting chronic inflammation and age-related, senescence-associated diseases, is advancing a pipeline led by HCW9302, an IL-2 fusion molecule in Phase 1 for alopecia areata, alongside two preclinical TRBC-based candidates aimed at improving T-cell engagement and immune checkpoint inhibition for solid tumors. The company also pursues business development through licensing deals that grant partners exclusive global rights to select proprietary molecules.
On February 26, 2026, HCW Biologics regained compliance with all Nasdaq Capital Market continued listing requirements, following an extension granted by a Nasdaq Hearings Panel in October 2025 to meet equity and other rules by deadlines in December 2025 and February 2026. The company remains under a one-year Mandatory Panel Monitor from January 7, 2026, during which any renewed breach of the equity listing rule could trigger an automatic delisting determination and a new hearing process, underscoring both the restored access to public capital and the ongoing compliance risk for shareholders and stakeholders.
The most recent analyst rating on (HCWB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
The score is held down primarily by very weak financial performance (sharp revenue decline, negative gross profit in TTM, persistent cash burn, and negative equity). Technicals also remain unfavorable with price below key longer-term moving averages and negative MACD. Offsetting factors are limited to positive corporate developments (financing/liability settlement to bolster equity and a Phase 1 trial start), which improve near-term positioning but do not yet change the fundamental risk profile.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary immunotherapies to treat diseases driven by chronic inflammation, particularly age-related and senescence-associated conditions such as cancer, autoimmune and neurodegenerative diseases. Its pipeline includes lead autoimmune candidate HCW9302, a first-in-kind IL-2 fusion molecule in a Phase 1 alopecia areata trial that began in November 2025, along with two preclinical TRBC platform-based candidates targeting solid tumors and immune checkpoint inhibition.
Average Trading Volume: 92,475
Technical Sentiment Signal: Sell
Current Market Cap: $3.11M
Find detailed analytics on HCWB stock on TipRanks’ Stock Analysis page.